Search Results

Microbion Receives Award at Advanced Wound Care Summit USA’s Innovation Showcase

Microbion Corporation announced that the company won the Advanced Wound Care Summit’s Innovation Showcase award.

April 25, 2024

·

4 min read

Microbion Selected to Present at Advanced Wound Care Summit USA

Microbion Corporation today announced that the company has been selected to present topical pravibismane for the treatment of diabetic foot infection (DFI) at the Advanced Wound Care Summit USA held at the Boston Marriot Long Wharf from April 16th to 17th.

April 15, 2024

·

3 min read

Drug Development

Microbion’s Topical Pravibismane Phase 1b Moderate or Severe Diabetic Foot Ulcer Infection Study is Published in International Wound Journal

Microbion Corporation today announced that the company has published results from its topical pravibismane Phase 1b study in the peer-reviewed International Wound Journal.

April 4, 2024

·

6 min read

FDA

Microbion’s Pravibismane Granted Second FDA Orphan Drug Designation for the Treatment of Non-tuberculous Mycobacterial (NTM) Infections

Microbion Corporation today announced that the company has been granted a second orphan drug designation for its lead drug candidate, pravibismane, for the treatment of non-tuberculous mycobacterial (NTM) infections.

January 30, 2024

·

4 min read

BioForest

Microbion CEO to Participate in Panel Discussion at BioFuture 2023

Microbion Corporation announced that Karim Lalji, CEO, will participate in a panel discussion during BioFuture 2023.

October 5, 2023

·

4 min read

Microbion Corporation CEO to Present at the 2023 BIO CEO & Investor Conference

Microbion Corporation, a clinical stage pharmaceutical company, announced that Karim Lalji, CEO of Microbion Pharma Corp., will be presenting at the 2023 BIO CEO & Investor Conference in New York, NY.

February 3, 2023

·

2 min read

Microbion Corp. Granted US Patent for the Use of Inhaled Pravibismane for Pulmonary Infections

Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued United States Patent No. 11,464,749 to Microbion with claims to the use of Microbion’s proprietary pravibismane inhaled composition for treatment of pulmonary infections.

April 4, 2023

·

3 min read

Microbion Presented New Pravibismane Data Against Mycobacteroides abscessus at the 6th World Bronchiectasis and NTM Conference

Microbion Corporation today announced that the company presented a poster highlighting the results from a series of in vitro and in vivo studies characterizing pravibismane’s effect against Mycobacteroides abscessus at the recent 6th World Bronchiectasis & NTM Conference held in New York, NY.

August 15, 2023

·

4 min read

Microbion Corporation Announces Granting of a US Patent for a Pharmaceutical Composition of Pravibismane

Microbion Corporation announced that the US Patent and Trademark Office issued to Microbion, United States Patent No. 11,324,715 on May 10, 2022, with claims to a pharmaceutical composition of pravibismane.

October 4, 2022

·

3 min read

Drug Development

Microbion Corporation Initiates Phase 2 Clinical Study Evaluating Topical Pravibismane Treatment of Diabetic Foot Infections

Microbion Corporation today announced that a Phase 2, randomized, controlled study has been initiated to assess the safety and efficacy of topical pravibismane for the treatment of subjects with moderate infections of chronic diabetic foot ulcers (DFU).

March 9, 2023

·

7 min read